Does Tirzepatide Cause Kidney Stones — What the Evidence Says

What the trial data and prescribing guidance actually record

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed 2,539 adults on tirzepatide across 72 weeks and collected detailed adverse-event data. Kidney stones did not appear as a treatment-emergent adverse event of note, and the medicine's current SmPC (the authoritative document that lists known risks) does not include nephrolithiasis among tirzepatide's recognised side effects. The NHS medicines page for tirzepatide similarly does not flag kidney stones as a concern associated with the drug's pharmacology.

That is the short answer. But it is not quite the whole picture, which is why this is a question our prescribers hear most weeks from people with a stone history who are considering treatment.

What the trials do record is a GI side-effect profile: nausea, vomiting, diarrhoea and constipation are common, particularly in the early weeks of treatment or after a dose increase. If those symptoms are severe enough to reduce fluid intake significantly, or if vomiting means a person cannot keep fluids down, urinary concentration rises. In susceptible individuals, concentrated urine is one of the conditions that favours stone formation, calcium oxalate and uric acid stones in particular. This is not a direct pharmacological effect of tirzepatide; it is a downstream consequence of inadequate hydration during GI upset. The distinction matters when weighing risk.

Why dehydration is the mechanism to watch, not the molecule itself

Kidney stones form when minerals in urine exceed their solubility threshold. The most common triggers are low urine volume, high urinary calcium, and raised oxalate or uric acid levels. If you want a detailed look at how tirzepatide relates to kidney stones, including what the evidence does and does not show about the drug's role, our dedicated page works through the question carefully. What it can do, via nausea and vomiting, is temporarily reduce how much fluid a person takes in.

For most people this is manageable: sipping water steadily throughout the day, eating smaller portions, and letting nausea settle as the body adjusts usually keeps hydration adequate. People who have previously formed stones may want to be more deliberate about this, and our page covering Mounjaro and kidney stones looks at the practical considerations for anyone with that history in more detail. Some specialists recommend aiming for pale urine as a practical guide during the early dose-escalation weeks. You can read more about how dose progression works on our Mounjaro overview page.

If you are also taking certain medicines that affect kidney function (NSAIDs, diuretics, or high-dose vitamin C supplements) your prescriber needs to know. The tirzepatide entry in the BNF summarises interaction considerations, though your prescriber will apply these to your specific medicines list. The combination of dehydration risk and a nephrotoxic medicine is a different calculation from tirzepatide alone.

If you already have kidney stones or reduced kidney function

A history of kidney stones does not automatically exclude you from tirzepatide treatment, but it is material information your prescriber needs before they can assess suitability. The same applies to chronic kidney disease, recurrent urinary tract infections, or a family history of stone disease. These are not listed contraindications in the SmPC; they are factors that shape the clinical conversation and may lead to additional monitoring, closer follow-up, or a different treatment plan.

Our page on taking Mounjaro with existing kidney stones looks at this scenario in more detail, and if your starting point is the more specific question of whether Mounjaro can cause kidney stones, that page examines the evidence and the indirect mechanisms in full. If you are experiencing flank pain, blood in the urine, or difficulty passing urine during treatment, seek medical attention rather than attributing the symptom to GI side effects and waiting for it to resolve.

It is worth being clear: pain in the abdomen or sides during tirzepatide use should not automatically be assumed to be a kidney stone. Pancreatitis, gallbladder problems, and kidney issues can all present with overlapping symptoms, and following the MHRA Yellow Card scheme, you can report any unexpected symptom so that post-marketing surveillance stays current. A prescriber or GP can distinguish between these causes far more reliably than self-diagnosis.

Starting treatment: what the consultation covers

Anyone starting tirzepatide through a clinically regulated private pharmacy goes through a structured assessment. At nume, that means a GPhC-registered Independent Prescriber reads your answers and medical history, a real clinician, the same day. Questions about kidney stones, urinary health, and relevant medicines you already take are part of that review. If you are on diuretics or have active stone disease, the prescriber may want more detail before approving treatment, or may raise the importance of specific monitoring. You can explore how the consultation works before you start, and read through common questions if you have others.

Hydration guidance during treatment, and what to do if nausea makes drinking difficult, is covered in the Patient Information Leaflet that comes with your pen. Personal advice on fluid targets or dietary changes should come from your prescriber or a dietitian rather than from general guidance online. Our Mounjaro pricing page explains what is included in a private prescription so there are no surprises about what aftercare looks like. The weight management overview is a good starting point if you are still deciding whether tirzepatide is the right route for you.